



**Ref. No.01/2026-Dir (MIS)**  
**Government of Pakistan**  
**Ministry of National Health Services Regulations & Coordination**  
**Drug Regulatory Authority of Pakistan**  
**Islamabad**  
\*\*\*\*\*

**Dated: January 08, 2026**

1. **The Chairman**  
**Pakistan Pharmaceutical Manufacturers Association (PPMA).**
2. **The Executive Director**  
**Pharma Bureau.**
3. **Pakistan Chemist & Druggist Association,**  
**Karachi, Pakistan**
4. **The Chairman**  
**KPPMA, Peshawar**

**Subject: Capacity Building & Technical Awareness sessions on 2-D Barcoding, Serialization and Harmonised Report Writing Performa for Inspection of Pharmaceutical Units**

The Drug Regulatory Authority of Pakistan (DRAP) is pleased to inform that, pursuant to the promulgation of the revised 2-D Barcode & Serialization Rules and SRO 1587 (I)/2025 dated 25 August 2025, regarding the amendment of the Drugs (Licensing, Registering and Advertising) Rules, 1976—whereby Schedule B-II has been replaced with the PIC/S Guidelines. The matter of implementation of the 2-D barcode and serialization requirements was deliberated with the pharmaceutical industry at the Office of the Honorable Federal Minister for National Health Services, Regulations & Coordination (NHS, R&C) and at DRAP Headquarter on 31<sup>st</sup> December 2025.


2. In this regard, DRAP intends to arrange capacity-building and technical awareness sessions for the pharmaceutical industry to facilitate the effective implementation of the revised rules/guidelines. Details of sessions arranged in Islamabad, Lahore and Karachi is already shared with industry wide even letter number dated January 06, 2026.

3. In view of above a session for KPK industry is hereby scheduled as details are given below.

Date & Time	City	Venue
15th Jan 2026, Thursday (9:30 am to 3:00 pm)	Peshawar	Sir Sahibzada Abdul Qayyum Museum Hall, University of Peshawar

3. The respective associations are requested to nominate focal persons and to disseminate this information among member companies and encourage active participation of relevant technical and regulatory staff. The cooperation in this important regulatory initiative shall be highly appreciated.

4. This issues with the approval of CEO, DRAP.

  
**Abdur Rahman Bin Tashfeen**  
Assistant Director (MIS)

**Copy to:**

1. CEO, Drug Regulatory Authority of Pakistan.
2. Additional Director Filed Office, Peshawar (with the request to coordinate with the respective associations to finalise the arrangements please and other logistic supports to DRAP Representatives)
3. All manufacturers of Allopathic Drugs/Importers, KPK